# Avaliação Genética - Genomic Unity® Whole Genome Analysis

**Date**: 2025-05-02
**Provider**: Variantyx
**Lab**: Variantyx Inc.
**Patient**: Isaac França
**DOB**: Jun 6, 2018
**Test ID**: 202806864 / 99658
**Report Type**: Re-Analysis (original issued Dec 14, 2024)

## Test Information

| Field | Value |
|-------|-------|
| Genetic Counselors | Rogerio R Rita and Richard Boles |
| Cohort | Trio |
| Sample Type | Saliva |
| Sample Collection Date | Sep 7, 2024 |
| Sample Received Date | Sep 11, 2024 |
| Processed Date | Mar 19, 2025 |
| Ordering Clinician | Rogério Rogério Rita |
| Lab Director | Christine M Stanley, PhD, FACMG ABMGG #2005163 |
| Signed By | Reena Ray Sisk PhD, FCCMG, DABMGG |

## Indication for Testing

- Autism
- Delayed speech and language development

## Included Analyses

- Small Sequence Variants
- Mitochondrial Genome
- Structural Variants
- Short Tandem Repeats

## Optional Findings

| Category | Status |
|----------|--------|
| ACMG Secondary Findings | Opted in |
| Actionable Findings | Opted in |

---

## Summary of Findings

**No pathogenic or likely pathogenic variants sufficient to cause disease were identified** that have been associated with the clinical symptoms provided.

**No variants were identified** in the American College of Medical Genetics and Genomics (ACMG) list of genes to be reported as secondary findings.

---

## Primary Findings

**No findings were identified.**

## ACMG Secondary Findings

**No variants meeting the ACMG recommendations** for reporting secondary findings were identified.

## Actionable Findings

**No other actionable findings** were identified at the time of reporting.

## Carrier Findings

**No carrier findings** were identified at the time of reporting.

---

## Variants of Uncertain Significance (VUS)

### MED13 - Other Variant

| Field | Value |
|-------|-------|
| Gene | MED13 |
| Transcript | NM_005121.3 |
| Variant | c.866A>T (p.Asp289Val) |
| dbSNP | rs925249026 |
| Classification | Uncertain Significance |
| Evidence | PP3_Moderate, PM2_Supporting |
| Mode of Inheritance | Autosomal dominant |
| Associated Condition | Intellectual developmental disorder 61 |
| gnomAD Frequency | 0.0022% |
| REVEL Score | 0.903 (predicted deleterious) |

**Inheritance Pattern:**
- Heterozygous in proband
- Heterozygous in father
- Not detected in mother

**Gene Function:** MED13 is part of the Mediator complex, which functions as a transcriptional coactivator. It regulates transcription by mediating interaction between RNA polymerase II and transcription factors. MED13 influences timing and amplitude of gene expression, particularly genes involved in cardiovascular development and metabolic pathways.

**Clinical Significance:** Pathogenic variants in MED13 are associated with autosomal dominant neurodevelopmental disorders. Based on current evidence, this variant is classified as uncertain for autosomal dominant intellectual developmental disorder 61.

---

## Supplementary Findings (Previously Reported)

### GALT Variant

| Field | Value |
|-------|-------|
| Gene | GALT |
| Transcript | NM_000155.4 |
| Variant | c.404C>T (p.Ser135Leu) |
| dbSNP | rs111033690 |
| Inheritance | Heterozygous in proband, Not detected in father, Heterozygous in mother |

### ASS1 Variant

| Field | Value |
|-------|-------|
| Gene | ASS1 |
| Transcript | NM_054012.4 |
| Variant | c.299G>A (p.Arg100His) |
| dbSNP | rs138279074 |
| Inheritance | Heterozygous in proband, Not detected in father, Heterozygous in mother |

### TAT Variant

| Field | Value |
|-------|-------|
| Gene | TAT |
| Transcript | NM_000353.3 |
| Variant | c.998G>A (p.Arg333His) |
| dbSNP | rs771408463 |
| Inheritance | Heterozygous in proband, Not detected in father, Heterozygous in mother |

### FHL1 Variant

| Field | Value |
|-------|-------|
| Gene | FHL1 |
| Transcript | NM_001159702.3 |
| Variant | c.617A>G (p.Gln206Arg) |
| dbSNP | rs915687031 |
| Inheritance | Hemizygous in proband, Not detected in father, Heterozygous in mother |

### Structural Variant - 3q26.31q26.32 Deletion

| Field | Value |
|-------|-------|
| Location | 3q26.31q26.32 |
| Size | 668.17 kb deletion |
| Coordinates (GRCh38) | chr3:175,361,472-176,029,643 |
| ISCN | seq[GRCh38] del(3)(q26.31q26.32)pat |
| Inheritance | Heterozygous in proband, Heterozygous in father, Not detected in mother |

---

## Sample Information

| Patient | ID | Sex | Date of Birth | Specimen Type | Date Collected | Date Received |
|---------|-----|-----|---------------|---------------|----------------|---------------|
| Proband (Isaac França) | 202806864 | M | Jun 6, 2018 | Saliva | Sep 7, 2024 | Sep 11, 2024 |
| Father | 202666150 | M | - | Saliva | Sep 7, 2024 | Sep 11, 2024 |
| Mother | 202666293 | F | - | Saliva | Sep 7, 2024 | Sep 11, 2024 |

---

## Pharmacogenomics Results

### Patient Genotype Summary

| Gene | Genotype | Metabolizer Status |
|------|----------|--------------------|
| CYP2B6 | *1/*1 | Normal Metabolizer |
| CYP2C19 | *1/*17 | Rapid Metabolizer |
| CYP2C9 | *1/*1 | Normal Metabolizer |
| CYP2D6 | *1/*4 | Intermediate Metabolizer |
| CYP3A5 | *3/*3 | Poor Metabolizer |
| CYP4F2 | *1/*1 | Indeterminate |
| DPYD | c.85T>C (*9A)/c.1896T>C | Normal Metabolizer |
| NAT2 | *4/*5 | Indeterminate |
| NUDT15 | *1/*1 | Normal Metabolizer |
| SLCO1B1 | *1/*14 | Normal Function |
| TPMT | *1/*1 | Normal Metabolizer |
| UGT1A1 | *1/*36 | Normal Metabolizer |
| VKORC1 | Reference/Reference | Indeterminate |

### Drugs with FDA Usage Notes Impact

#### CYP2D6 Intermediate Metabolizer (*1/*4) - May Alter Systemic Concentrations

| Drug | Brand Name | Category | Impact |
|------|------------|----------|--------|
| Amitriptyline | Elavil® | Antidepressant | May alter systemic concentrations |
| Clomipramine | Anafranil® | Antidepressant | May alter systemic concentrations |
| Desipramine | Norpramin® | Antidepressant | May alter systemic concentrations |
| Doxepin | Sinequan® | Antidepressant | May alter systemic concentrations |
| Imipramine | Tofranil® | Antidepressant | May alter systemic concentrations |
| Nortriptyline | Pamelor® | Antidepressant | May alter systemic concentrations |
| Amoxapine | - | Antidepressant | May alter systemic concentrations |
| Paroxetine | - | Antidepressant | May alter systemic concentrations |
| Trimipramine | - | Antidepressant | May alter systemic concentrations |
| Tamoxifen | - | Oncology | Lower systemic active metabolite concentrations |

#### Drugs with Therapeutic Management Recommendations

| Drug | Gene | Metabolizer Status | FDA Notes |
|------|------|--------------------|-----------|
| Meclizine | CYP2D6 (*1/*4) | Intermediate | May affect systemic concentrations. Monitor for adverse reactions and clinical effect. |
| Eliglustat | CYP2D6 (*1/*4) | Intermediate | Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Dosages based on CYP2D6 status. |

#### Drugs Requiring Additional Assessment

| Drug | Gene | Status | Notes |
|------|------|--------|-------|
| Amifampridine | NAT2 (*4/*5) | Indeterminate | Follow up with additional risk assessment |
| Amifampridine Phosphate | NAT2 (*4/*5) | Indeterminate | Follow up with additional risk assessment |

### Psychology/Psychiatry Medications

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Amphetamine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Aripiprazole | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Aripiprazole Lauroxil | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Atomoxetine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Brexpiprazole | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Citalopram | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Clozapine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Escitalopram | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Fluvoxamine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Iloperidone | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Pimozide | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Risperidone | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Thioridazine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Venlafaxine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Vortioxetine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |

### Neurology Medications

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Brivaracetam | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Clobazam | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Deutetrabenazine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Tetrabenazine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Valbenazine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Donepezil | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Galantamine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |

### Anesthesiology/Pain Medications

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Codeine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Tramadol | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Lofexidine | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Carisoprodol | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Diazepam | CYP2C19 (*1/*17) | Rapid | No available recommendation |

### Gastroenterology (Antacids)

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Metoclopramide | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Pantoprazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Dexlansoprazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Esomeprazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Omeprazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Rabeprazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |

### Hematology/Anticoagulants

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Clopidogrel | CYP2C19 (*1/*17) | Rapid | No available recommendation |
| Warfarin | CYP2C9 (*1/*1) | Normal | No available recommendation |
| Warfarin | CYP4F2 (*1/*1) | Indeterminate | No available recommendation |
| Warfarin | VKORC1 (Ref/Ref) | Indeterminate | No available recommendation |

### Cardiology

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Propafenone | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Carvedilol | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Metoprolol | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Nebivolol | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Propranolol | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Simvastatin | SLCO1B1 (*1/*14) | Normal Function | No available recommendation |
| Rosuvastatin | SLCO1B1 (*1/*14) | Normal Function | No available recommendation |

### Transplant Medicine

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Tacrolimus | CYP3A5 (*3/*3) | Poor | No available recommendation |

### Oncology

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Capecitabine | DPYD | Normal | No available recommendation |
| Fluorouracil | DPYD | Normal | No available recommendation |
| Gefitinib | CYP2D6 (*1/*4) | Intermediate | No available recommendation |
| Irinotecan | UGT1A1 (*1/*36) | Normal | No available recommendation |
| Mercaptopurine | TPMT/NUDT15 | Normal | No available recommendation |
| Thioguanine | TPMT/NUDT15 | Normal | No available recommendation |

### Infectious Disease

| Drug | Gene | Metabolizer Status | Recommendation |
|------|------|--------------------|-----------------|
| Efavirenz | CYP2B6 (*1/*1) | Normal | No available recommendation |
| Dolutegravir | UGT1A1 (*1/*36) | Normal | No available recommendation |
| Raltegravir | UGT1A1 (*1/*36) | Normal | No available recommendation |
| Voriconazole | CYP2C19 (*1/*17) | Rapid | No available recommendation |

---

## Follow-Up Recommendations

Genetic counseling is recommended to review both positive and negative results. Test results may benefit from periodic reevaluation for new clinical associations to variants and updated variant classification.

---

## Methods

- **Sequencing**: Whole genome short read sequencing by next generation sequencing (NGS)
- **Platform**: Variantyx Genomic Intelligence® platform version 3.17.5.3
- **Confirmation**: Orthogonal confirmation performed as needed by Oxford Nanopore Technologies (ONT) PromethION 24
- **Reference Genome**: GRCh38

### Statistics

| Metric | Value |
|--------|-------|
| SNV Sensitivity/Specificity/PPV | >0.99 |
| Small indel (<50bp) Sensitivity | >0.95 |
| Small indel (<50bp) PPV | >0.92 |
| CNV (>300bp) Sensitivity | >0.80 |
| CNV (any size) Clinical Sensitivity | >0.96 |
| Pathogenic STR Clinical Sensitivity | >0.99 |
| PGx Diploid Genotype Sensitivity | >0.96 |
| PGx Specificity/PPV | >0.98 |

---

*Source: /Users/tony/isaacstory/isaacstory2/Exams/Genetic/20250502_Variantyx_AvaliacaoGenetica.pdf*
*Generated: 2026-01-28*
*Template: Genetic v1.0*